IUHC:LSE:LSE-iShares S&P 500 USD Health Care Sector UCITS (USD)

ETF | Others |

Last Closing

USD 11.62

Change

-0.09 (-0.73)%

Market Cap

USD 2.66B

Volume

0.19M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.04 (-0.37%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+4.50 (+2.37%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1.28 (-0.91%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.08 (+0.42%)

USD 559.82B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.44%)

USD 500.71B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.06%)

USD 266.08B
0QZO:LSE 0QZO

+0.15 (+0.16%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.11 (+0.35%)

USD 204.07B
0QZ3:LSE Qualcomm Inc.

-4.06 (-2.34%)

USD 202.26B

ETFs Containing IUHC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.21% 60% D- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.21% 60% D- 61% D-
Trailing 12 Months  
Capital Gain 20.85% 59% D- 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.85% 59% D- 60% D-
Trailing 5 Years  
Capital Gain 66.36% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.36% 78% C+ 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.23% 69% C- 71% C-
Dividend Return 11.23% 68% D+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.53% 64% D 79% B-
Risk Adjusted Return 106.73% 96% N/A 98% N/A
Market Capitalization 2.66B 91% A- 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike